Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

Perpetual Observational Study - Ventilator Associated Pneumonia

NCT05719259 · tracked via the Priya Life Science Italy tracker
Phase
Observational
Started
2022-08-03
Last updated
2026-09-10

Condition(s) studied

Ventilator Associated Pneumonia

Study summary

Ventilator-Associated Pneumonia (VAP) is a bacterial respiratory infection that patients in the Intensive Care Unit (ICU) often get when they cannot breathe for themselves and require mechanical ventilation. It is linked to higher chances of death, a longer stay in the hospital, higher costs, and the use of more antibiotics.

Options to help prevent or treat this disease are in development and will require evaluation in future clinical trials.

The goal of POS-VAP is to build and continuously train a network of ICUs to be prepared for doing these trials, to facilitate their execution.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion criteria: * Age≥18 years * At risk of acquiring VAP during ICU stay, defined as: * Requiring admission or being admitted to the ICU. * Expected or documented to be under IMV for more than 48 hours. * Consent, either a written informed consent given by the study patient in full medical, psychological, cognitive, social or legal capacity to give an informed consent, or, if not possible, by a Legally Authorized Representative of the study patient OR any applicable locally accepted form of consent OR consent waiver allowing data collection and sharing of data according to ECRAID's principles Exclusion Criteria: * Death is deemed to be imminent or inevitable during this hospital admission AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment.

Primary outcome measure(s)

  • Number of research sites recruiting patients — 4 years
    POS-VAP' overarching objective is to build a sustainable European clinical research network of ICUs that serves as platform to facilitate observational and randomized VAP research activities. This objective will be measured by in three ways: 1\. Total number of sites in the POS-VAP network that actively recruit patients
  • Number of patients recruited in the study — 4 years
    2\. Total number of patients in the POS-VAP network per analysis population (enrolled population, VAP population and microbiologically evaluable VAP population).
  • Number of studies implemented through the network — 4 years
    3\. Total number of implemented observational studies and RCTs (stratified by domain: prevention, diagnosis and treatment).

Trial sites (35)

FacilityCityRegionStatus
University Hospital of Trauma Tirana Albania Recruiting
Cliniques Universitaires Saint-Luc UCL Brussels Belgium Recruiting
Universitair Ziekenhuis Gent Ghent Belgium Recruiting
Hôpital de Jolimont La Louvière Belgium Recruiting
Centre Hospitalier Universitaire de Liège Liège Belgium Not Yet Recruiting
Clinique Saint Pierre Ottignies Ottignies-Louvain-la-Neuve Belgium Active Not Recruiting
Clinical Hospital Center Rijeka Rijeka Croatia Recruiting
General Hospital "Dr. Josip Benčević" Slavonski Brod Slavonski Brod Croatia Recruiting
University Hospital for Infectious Diseases Zagreb Croatia Not Yet Recruiting
University Hospital Kralovske Vinohrady Brno-Vinohrady Czechia Recruiting
University Hospital Motol Prague Czechia Recruiting
Centre Hospitalier William Morey Chalon-sur-Saône France Recruiting
Centre Hospitalier Universitaire Dijon Bourgogne Dijon France Recruiting
Centre Hospitalier de Le Mans Le Mans France Recruiting
Centre Hospitalier Régional Universitaire de Lille Lille France Recruiting
Centre Hospitalier Universitaire Dupuytren of Limoges Limoges France Recruiting
Centre Hospitalier Universitaire de Tours Tours France Recruiting
University Hospital Leipzig Leipzig Germany Not Yet Recruiting
University Hospital of Alexandroupolis Alexandroupoli Greece Not Yet Recruiting
Evangelismos General Hospital of Athens Athens Greece Not Yet Recruiting
Sotiria Thoracic Diseases Hospital of Athens Athens Greece Not Yet Recruiting
General University Hospital of Larissa Larissa Greece Not Yet Recruiting
IRCCS Ospedale Policlinico Gemelli Roma Italy Not Yet Recruiting
Deventer Ziekenhuis Deventer Netherlands Recruiting
University Medical Center Utrecht Utrecht Netherlands Recruiting
Central Military Emergency University Hospital Dr. Carol Davila Bucharest Romania Recruiting
Elias University Emergency Hospital Bucharest Romania Recruiting
University Clinical Center of Serbia Belgrade Serbia Recruiting
Hospital Universitario Reina Sofia Córdoba Cordoba Recruiting
Hospital Universitario Central de Asturias Oviedo Principality of Asturias Recruiting
IMED Valencia Burjassot Valencia Recruiting
Vall d'Hebrón University Hospital Barcelona Spain Active Not Recruiting
John V Farman Intensive Care Unit Cambridge United Kingdom Not Yet Recruiting
Royal Infirmary of Edinburgh Edinburgh United Kingdom Not Yet Recruiting
Royal Victoria Infirmary Newcastle United Kingdom Not Yet Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05719259 on ClinicalTrials.gov ↗ ← All trials in Italy